In the News

Toothful or Toothless? Biden's Biosimilar Bills Under the Microscope, The Center for Biosimilars

April 27, 2021

Partner Christopher Betti spoke with The Center for Biosimilars about the Biden-Harris administration’s Ensuring Innovation Act and Advancing Education on Biosimilars Act of 2021. In the article Chris noted that the former has its roots in efforts to break through originator biologic patent barriers that may prevent biosimilar developers from bringing their drugs to market, but in its approved form it is not capable of advancing that mission. While the Ensuring Innovation Act changes the language of the Federal Food, Drug, and Cosmetic Act, “this change has no effect on the biosimilars market and no effect on the exclusivity that is already given to biologics,” said Chris. 

Read the full The Center for Biosimilars article >>